human hepatic stellate cells were evaluated. We found that serum CXCL6 level increased gradually with disease progression of CHB, and there was positive correlation between serum CXCL6 level and alanine transaminase (ALT) and aspartate transaminase (AST). In vitro, CXCL6 promoted L02 proliferation but this was blocked upon CXCR1 knockdown. The level of phospho-IκBα was upregulated by CXCL6 but downregulated by CXCR1 siRNA in L02 cells. CXCL6 inhibited the secretion of COLI by LX2 cells, dependent on CXCR1 and CXCR2. Taken together, these data suggest that increased expression of CXCL6 during CHB could promote hepatocyte proliferation through CXCR1/NF-κB pathway and inhibit the secretion of COLI by hepatic stellate cells.
Hepatocyte proliferation and collagen I (COLI) degradation are important processes during liver regeneration (Oyanagi et al. 2014 ).
Inflammatory mediators, such as the CXC chemokines, are essential in the response to hepatic injury (Clarke et al. 2009 ). CXC chemokines are subdivided into two subsets based on the presence or absence of a Glu-Leu-Arg (ELR) motif at the amino terminus.
ELR-positive CXC chemokines include epithelial neutrophil-activating protein (ENA-78), macrophage inflammatory protein-2 (MIP-2), granulocyte chemotactic protein-2 (GCP2/CXCL6) and interleukin 8 (IL8), which possess the ELR motif to the CXCR1 and CXCR2 receptors (Mantovani et al. 2006 ). CXCR1 and CXCR2 are expressed in neutrophils, endothelial cells, and hepatocytes (Cao et al. 2000 , Murphy 2002 . CXC chemokines bind CXCR1/CXCR2 and promote hepatocyte proliferation (Colletti et al. 1998 , Ren et al. 2003 . In addition, CXCR1 promotes liver repair by facilitating recovery after ischemia/reperfusion (I/R) injury (Kuboki et al, 2008) . In virus-induced liver injury, CXCL6 was upregulated in liver specimens of chronic hepatitis C patients (Asselah et al, 2005) . However, the underlying mechanism remains unknown.
In this study we aimed to investigate the role and mechanism of CXCL6 in CHB. We collected the serum from 50 patients with CHB, detected serum CXCL6 level and analyzed clinical data of these patients. Next, we explored the effect and mechanism of CXCL6 on hepatocyte proliferation and the secretion of COLI from hepatic stellate cells.
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Methods
Patients
Fifty CHB patients (age range 27-59 years, male-to-female ratio 37:13) who were HBsAg positive for at least 6 months were treated at Shanghai General Hospital between 2008 and 2010.
Patients with the following characteristics were excluded: HIV or HCV co-infection, consumption of more than 30 g alcohol per day, having received anti-viral treatment, or insufficient liver biopsy tissue (a minimum length of 1.0 cm with at least six portal tracts was required). CHB patients with end-stage liver disease were excluded. This study was approved by our institutional ethics committee and informed consent was obtained from all patients prior to participation. All patients underwent percutaneous liver biopsy to determine fibrotic stage and inflammation grade, according to Scheuer's classification (Scheuer 1995).
Cell culture
L02 human hepatocyte cell line was purchased from the Cell Bank of Shanghai Institutes of Life Sciences, and LX-2 human hepatic stellate cell line was kindly provided by the Laboratory Diagnostic Division of Shanghai Changzheng Hospital. Hepatocytes were maintained in 1640 medium (Gibco) containing 10% fetal bovine serum (FBS), and HSCs were grown in DMEM medium (Gibco) containing 10% FBS.
ELISA
Serum CXCL6 protein and COLI of cell culture supernatant were examined using enzyme-linked immunosorbent assay (ELISA) kits (WESTANG BIO-TECH CO, China) according to the manufacturer's instructions.
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Real-time PCR
Total RNA was extracted from cells using Trizol and was reverse-transcribed using an iScript cDNA kit (TAKARA, Japan). Real-time PCR was performed on an iCycler system using SYBR Green Master Mix (TAKARA). Primer specificity was confirmed by sequencing PCR products. GAPDH was used as the internal control. Data were presented according to the ∆∆Ct method.
Western blot analysis
Cultured cells were homogenized in ice-cold RIPA buffer containing protease and phosphatase inhibitors (Sigma, USA). Cell lysate was separated on 10% Bis-Tis gradient gel (Invitrogen, USA), transferred to a PVDF membrane, then incubated with antibody to following the manufacturer's instructions.
MTT assay
Cells were plated in 96-well culture plates (1×10 3 cells per well) and incubated for 1 to 3 days.
Then, 20 µl of 5 mg/ml of MTT solution was added to each well and incubated for 4 h at 37ºC. The media were removed from each well, and the resultant MTT formazan was solubilized in 150 µl of DMSO. The absorbance values at 492 nm were measured using a micro-plate reader (Bio-Rad).
The experiment was repeated three times and each experiment had six replicate wells.
Statistical analysis
Data were expressed as the mean ± standard deviation and were representative of at least three separate experiments. Comparisons were performed using ANOVA and correlation was determined using Pearson's correlation coefficient. A p-value of less than 0.05 was considered significant.
Results
CXCL6 level is high in the serum of CHB patients
The demographic characteristics and histologic data for CHB patients are summarized in Table 1 . A trend toward a higher serum level of CXCL6 in CHB patients was observed from S0 to D r a f t 7 S4. Serum CXCL6 level was significantly higher in CHB patients with Scheuer fibrosis score S0-S1 than in those with S2-S4 (P=0.001, Fig. 1 ). Furthermore, we examined the association of serum CXCL6 level with alanine transaminase (ALT), aspartate transaminase (AST), platelets (PLT), international normalized ratio (INR), total bilirubin (TB), and direct bilirubin (DB) ( Table   2 ). From stage S0 to S4, we observed significant association of serum CXCL6 level with ALT and AST.
CXCL6 promotes hepatocyte proliferation in vitro
We treated L02 human hepatocytes with different concentrations of CXCL6 and evaluated hepatocyte proliferation. MTT assay showed that CXCL6 stimulated hepatocyte proliferation in a time and concentration dependent manner (Fig. 2) . In particular, the proliferation of L02 cells was significantly increased after treatment with 100 ng/ml CXCL6 for 48 h, compared to treatment with 1 ng/ml or 10 ng/ml CXCL6, while longer treatment (72 h) led to reduced proliferation of L02 cells (Fig. 2) . Therefore, we selected the concentration of CXCL6 at 100 ng/ml and treatment time at 48 h for the following experiments.
Next we detected the expression of CXCL6 receptors CXCR1 and CXCR2 in L02 cells by immunocytofluorescence. While we observed that hepatocyte marker alubmin was stained as green in the cytoplasm, CXCR1 and CXCR2 were stained as red in the membrane, the cytoplasm and the nucleus (Fig. 3A) . To investigate the role of CXCR1 and CXCR2 in mediating the effect of CXCL6 on hepatocyte proliferation, we employed siCXCR1 and siCXCR2 to knockdown CXCR1 and CXCR2 in L02 cells, as confirmed by real-time PCR analysis (Fig. 3B) Fig. 3C ).
Furthermore, after treatment with CXCL6 (100 ng/ml) L02 cells showed significantly increased level of phospho-IκBα (P<0.05), but the levels of total STAT3 and p-STAT3
showed no significant difference (P>0.05; Fig. 4A ). Meanwhile, the levels of phospho-IκBα, STAT3, and p-STAT3 were decreased after the cells were treated with siCXCR1 ( Fig. 4B ). In contrast, in cells treated with siCXCR2, only p-STAT3 level was decreased while the levels of phospho-IκBα and total STAT3 showed no significant difference (Fig. 4C ). These data suggest that CXCR1 and CXCR2 have different role in mediating the effect of CXCL6 on hepatocyte proliferation.
CXCL6 inhibits COLI secretion from human hepatic stellate cells
Next we aimed to investigate the effect of CXCL6 on collagen secretion by hepatic stellate cells. ELISA assay showed that after treatment with CXCL6, COLI level in the supernatant of LX2 cells was decreased (P<0.05; Fig. 5A ). To investigate the role of CXCR1 and CXCR2 in mediating the effect of CXCL6 on collagen secretion, we employed siCXCR1 and siCXCR2 to knockdown CXCR1 and CXCR2 in LX2 cells (Fig.   5B ). Treatment with siCXCR1 or siCXCR2 resulted in no significant difference in the proliferation of LX2 cells compared with siControl group (Fig. 5C ), but caused significant increase in COLI level in the supernatant of LX2 cells (P<0.05; Fig. 5D ). These data suggest that CXCR1 and CXCR2 play important role in mediating the effect of CXCL6 on collagen secretion from hepatic stellate cells.
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Discussion
CXCL6 is an important chemokine involved in the pathogenesis of liver fibrosis. In this study we demonstrated that serum CXCL6 level increased along with liver disease progression in CHB patients. We also found a close association between serum CXCL6
level and biochemical markers of liver function. The potential mechanism is that CXCL6
promotes hepatocyte proliferation through CXCR1/NF-κB signaling, while inhibits COLI secretion from human hepatic stellate cells synergistically with CXCR1 and CXCR2.
Consistent with a previous study (Colletti et al. 1998) , we found that CXCL6 (10-1000 ng/ml) promoted hepatocyte proliferation and hepatocyte proliferative capacity was the highest when cells were treated with 100 ng/ml CXCL6 for 48 h. However, when CXCL6 concentration was between 100 and 1000 ng/ml, proliferative capacity could not be increased further with the increase in CXCL6 concentration. This may be related to the availability of CXCL6 receptors. CXCL6 should bind with CXCR1 and/or CXCR2 to exert biological effects (Mantovani et al. 2006) . If the receptors are saturated, even higher concentration of CXCL6 could not exert additional effects.
By using siRNA to knockdown CXCL6 receptors, we found that the effects of CXCL6 on hepatocyte proliferation could be mediated by CXCR1. Upon CXCR1 knockdown, CXCL6 could not promote hepatocyte proliferation. Meanwhile, even without CXCL6 stimulation, CXCR1 can regulate hepatocyte proliferation. In contrast, upon CXCR2 knockdown, CXCL6 could still promote hepatocyte proliferation. These results suggest that CXCR1 is the critical receptor for CXCL6 to promote hepatocyte proliferation, and hepatocytes can secrete other chemokines to maintain their proliferation through CXCR1. Furthermore, we found that siCXCR1 decreased not only phospho-IκBα level but also total STAT3 and p-STAT3 levels. Considering these results, we postulate that CXCL6/CXCR1/NF-κB signaling is the primary pathway through which CXCL6
promotes human hepatocyte proliferation, and CXCR1 may participate in STAT3 signaling pathway through other ligands.
Another interesting observation from our study is that CXCL6 inhibited COLI secretion from human hepatic stellate cells. Inhibition of COLI secretion is the key factor in promoting hepatocyte proliferation in vivo (Iimuro et al. 2003) . HSC is the major source of COLI (Issa et al. 2003) . Therefore, we examined the impact of CXCL6 on COLI secretion by LX2 cells. We found that CXCL6 (100 ng/ml) significantly inhibited the secretion of COLI from LX2 in vitro. However, after CXCR1 or CXCR2 knockdown, CXCL6 could not inhibit COLI secretion by LX2 cells. These data indicate that CXCL6 could inhibit the secretion of COLI from HSC through CXCR1 and CXCR2 pathways. Interestingly, a recent study using LX2 cells showed that HSC could promote hepatocellular carcinoma cell invasion through SDF-1/CXCR4 pathway (Li et al. 2014 ). These results suggest that CXC chemokine family members play diverse role in HSC.
In conclusion, we demonstrated that CXCL6 not only promotes hepatocyte proliferation through CXCR1/NF-κB pathway, but also inhibits the secretion of COLI from HSC through the synergistic effects of CXCR1 and CXCR2. In the natural history of chronic 
